I came across this 2023 article and i think it poses a great outcome for us who are cycling high T and darolutamide.
Am I correct that this article correlates positively with our BAT with Daro?
I find this article extremely fascinating although it is complex. I need to learn more about proteonomic or onomics for that matter and its effects on transcription.
We report for the first time the impact of the newly approved AR antagonist darolutamide using a very sensitive, label-free, global mass spectrometry–based approach and show a much better concordance between the regulation of protein and mRNA levels than found in previous studies with other compounds. Importantly, darolutamide is structurally different from other second-generation AR antagonists, such as enzalutamide and apalutamide. It is characterized by a flexible polar-substituted pyrazole structure, which leads to unique interactions within the AR ligand-binding pocket and to differential recruitment of cofactors compared to other AR antagonists [16], and to differences in the downstream regulated genes [62].
Comparative Proteomic and Transcriptomic Analysis of the Impact of Androgen Stimulation and Darolutamide Inhibition
ncbi.nlm.nih.gov/pmc/articl...
Simple Summary
Abstract
Several inhibitors of androgen receptor (AR) function are approved for prostate cancer treatment, and their impact on gene transcription has been described. However, the ensuing effects at the protein level are far less well understood. We focused on the AR signaling inhibitor darolutamide and confirmed its strong AR binding and antagonistic activity using the high throughput cellular thermal shift assay (CETSA HT). Then, we generated comprehensive, quantitative proteomic data from the androgen-sensitive prostate cancer cell line VCaP and compared them to transcriptomic data. Following treatment with the synthetic androgen R1881 and darolutamide, global mass spectrometry-based proteomics and label-free quantification were performed. We found a generally good agreement between proteomic and transcriptomic data upon androgen stimulation and darolutamide inhibition. Similar effects were found both for the detected expressed genes and their protein products as well as for the corresponding biological programs. However, in a few instances there was a discrepancy in the magnitude of changes induced on gene expression levels compared to the corresponding protein levels, indicating post-transcriptional regulation of protein abundance. Chromatin immunoprecipitation DNA sequencing (ChIP-seq) and Hi-C chromatin immunoprecipitation (HiChIP) revealed the presence of androgen-activated AR-binding regions and long-distance AR-mediated loops at these genes.
3.3. Androgen Stimulation and Darolutamide Inhibition Induce Largely Concordant Changes at the Gene and Protein Levels
We then focused on genes and proteins differentially expressed in cells treated by the androgen and darolutamide combination, compared to androgen treatment alone. Remarkable effects on known androgen-regulated genes and other androgen-dependent pathways, such as cholesterol homeostasis, fatty acid metabolism, unfolded protein response and cell cycle, were observed upon R1881 plus darolutamide application (Figure 3C). Scatter plot analysis showed a strong negative correlation between changes induced by R1881 compared to R1881 plus darolutamide, both in RNA (Figure S2A) and protein (Figure S2B) levels, demonstrating that darolutamide potently reverted expression changes induced by R1881. While hundreds of genes were found up- or down-regulated two-fold and more on the transcriptional level following treatment with R1881 and darolutamide, compared to R1881 alone, the magnitude of change was lower in the protein levels, with fewer proteins passing the two-fold threshold (Table S1).
Go to:
4. Discussion
………,
Androgen treatment strongly induced gene expression programs related to cell proliferation and survival, both at the transcription and protein expression levels.
The stimulatory effects we observed following androgen application were potently reverted by additional darolutamide treatment, in line with the high anti-proliferative activity of this compound in androgen-dependent prostate cancer models and its efficacy in the clinic [24,25,49]……..,